ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Dendritic cells"

  • Abstract Number: 0839 • ACR Convergence 2020

    Single-Cell Transcriptomics of Mouse and Human Lupus Nephritis Identifies Conserved Myeloid Populations Across Species

    Paul Hoover1, Michael Peters2, David Lieb3, Rakesh Mishra4, Nir Hacohen2 and Anne Davidson5, 1Brigham and Women's Hospital, Boston, MA, 2Broad Institute, Boston, 3Broad Institute, Boston, MA, 4Feinstein Institute, Manhasset, NY, 5Northwell Health, New York

    Background/Purpose: We recently identified novel immune cell states in the kidneys of lupus nephritis patients (Arazi et al, Nature Immunology 2019). To determine the similarities…
  • Abstract Number: 0851 • ACR Convergence 2020

    Iberdomide Decreases B Cells and Plasmacytoid Dendritic Cells, Increases Regulatory T Cells and IL-2, and Has Enhanced Clinical Efficacy in Active Systemic Lupus Erythematosus Patients with High Aiolos or the IFN Gene Expression Signature

    Peter Lipsky1, Ronald van Vollenhoven2, Thomas Dörner3, Victoria Werth4, Joan Merrill5, Richard Furie6, Milan Petronijevic7, Benito Velasco Zamora8, Maria Majdan9, Fedra Irazoque-Palazuelos10, Robert Terbrueggen11, Nikolay Delev12, Michael Weiswasser12, Shimon Korish12, Nataliya Agafonova12, Mark Stern13, Sarah Hersey13, Ying Ye13, Allison Gaudy12, Zhaohui Liu12, Shaojun Tang13 and Peter Schafer12, 1RILITE Foundation, Charlottesville, VA, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3DRFZ and Charité University Hospitals, Berlin, Germany, 4University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 7Military Medical Academy, Belgrade, Serbia, 8Instituto CER S.A., Buenos Aires, Argentina, 9Medical University of Lublin and Samodzielny Publicnzy Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland, 10Centro de Investigación y Tratamiento Reumatológico S.C, Miguel Hidalgo, Mexico, 11DxTerity Diagnostics Inc, Rancho Dominguez, 12Bristol Myers Squibb, Princeton, 13Bristol-Myers Squibb, Princeton

    Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…
  • Abstract Number: 0861 • ACR Convergence 2020

    Hydroxychloroquine Use Is Associated with Diminished Type I Interferon-related Pathways in Systemic Lupus Erythematosus Patients

    Samantha Slight-Webb1, Kevin Thomas1, Rufei Lu1, Susan Macwana1, Joan Merrill1, Cristina Arriens1, Eliza Chakravarty1, Teresa Aberle1, Holden Maecker2, Paul Utz3, Joel Guthridge1 and Judith James4, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, 3Stanford University School of Medicine, Stanford, CA, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK

    Background/Purpose: Hydroxychloroquine (HCQ) has been used for decades to treat systemic lupus erythematosus (SLE) and is associated with decreased lupus flares and damage. However, despite…
  • Abstract Number: 0979 • ACR Convergence 2020

    The Identification of Shared and Unique Myeloid Cell States in Pre- and Post-nephritic Lupus Mouse Models, Sle.Yaa1 and NZBW

    Paul Hoover1, Michael Peters2, David Lieb3, Heather Geiger4, Rakesh Mishra5, Nir Hacohen2 and Anne Davidson6, 1Brigham and Women's Hospital, Boston, MA, 2Broad Institute, Boston, 3Broad Institute, Boston, MA, 4New York Genome Center, New York, NY, 5Feinstein Institute, Manhasset, NY, 6Northwell Health, New York

    Background/Purpose:Poor renal prognosis in lupus nephritis (LN) is associated with an abundance of renal macrophages and dendritic cells (DCs) but the role of these cells…
  • Abstract Number: 1404 • ACR Convergence 2020

    Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry

    Jay Patel1, Spandana Maddukuri2, Yubin Li3, Christina Bax4 and Victoria Werth3, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 3University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, 4University of Pennsylvania, Department of Dermatology, Philadelphia

    Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
  • Abstract Number: 1949 • ACR Convergence 2020

    CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro

    Spandana Maddukuri1, Jay Patel2, Christina Bax3, Maria Wysocka3 and Victoria Werth4, 1University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, 2University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, 3University of Pennsylvania, Department of Dermatology, Philadelphia, 4University of Pennsylvania and Corporal Michael J. Crescenz Veterans Administration Hospital, Philadelphia

    Background/Purpose: Dermatomyositis (DM) patients report poor quality of life due to disease activity and persistent itch. Lenabasum is an oral non-immunosuppressive, non-psychoactive cannabinoid type 2…
  • Abstract Number: 58 • 2019 ACR/ARP Annual Meeting

    In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets

    Christian Geier1, Jon Giles 2, Gilad Gibor 3, Joan Bathon 2 and Robert Winchester 3, 1Columbia University, New York, NY, 2Division of Rheumatology, Columbia University, New York, NY, 3Columbia University, New York

    Background/Purpose: Dendritic cells (DC) are specialized antigen-presenting cells (APC) that have a central role in the initiation of immune responses. However, prior studies showed numeric decreases…
  • Abstract Number: 984 • 2019 ACR/ARP Annual Meeting

    Important Role of CD11c+ Cells in Inflammatory Arthritis

    Antonia Puchner1, Elisabeth Simader 1, Victoria Saferding 2, Gerhard Kroenke 3, Rene Pfeifle 4, Daniel Aletaha 1, Josef Smolen 1 and Stephan Blueml 1, 1Medical University of Vienna, Vienna, Austria, 2Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 3Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Austria, 4University Hospital Erlangen, Erlangen, Germany

    Background/Purpose: Dendritic cells (DCs) are important antigen presenting cells (APCs) and therefore they play an important role in bridging the innate and the adaptive immune…
  • Abstract Number: 1064 • 2019 ACR/ARP Annual Meeting

    CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy

    Ross Lindsay1, Janice Chen 1, Robert Spiera 2, Jessica Gordon 2, Marie-Dominique Ah Kioon 3, Franck Barrat 3 and Christopher Brooks 1, 1Stemline Therapeutics, New York, 2Hospital for Special Surgery, New York, NY, 3HSS Research Institute, Hospital for Special Surgery, New York

    Background/Purpose: Tagraxofusp is a novel targeted therapy directed to the interleukin-3 receptor (CD123). Tagraxofusp is comprised of human IL-3 recombinantly fused to a truncated diphtheria…
  • Abstract Number: 97 • 2018 ACR/ARHP Annual Meeting

    Enhanced IFN-α Production By Plasmacytoid Dendritic Cells Is Associated with Increased Toll-like Receptor 7 Retention in the Lysosomes and Exosure to Type I IFN in Systemic Lupus Erythematosus

    Goh Murayama1, Asako Chiba2, Ayako Makiyama2, Ken Yamaji1, Naoto Tamura1 and Sachiko Miyake2, 1Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Immunology, Juntendo University School of Medicine, Tokyo, Japan

    Background/Purpose: Type I interferon(IFN) appears to contribute to the development of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes has been reported…
  • Abstract Number: 845 • 2018 ACR/ARHP Annual Meeting

    New Insights in Lupus Dermatitis: Differential Regulation and Roles of Tissue-Resident Dendritic Cell Subsets in the Pathogenesis of Autoimmune Skin Inflammation

    Ram R. Singh, Miguel-Angel Gutierrez, Peter Kim, Darshan Randhawa, Rachael Philips, Jennifer K. King and Anna Eriksson, Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA

    Background/Purpose: Acquired or self antigens in tissues are taken to lymphoid organs to elicit protective immunity or tolerance, respectively. This is accomplished by dendritic cells…
  • Abstract Number: 1018 • 2018 ACR/ARHP Annual Meeting

    Tofacitinib Impairs Monocyte-Derived Dendritic Cell Differentiation in Rheumatoid Arthritis and Psoriatic Arthritis.

    Viviana Marzaioli1, Mary Canavan1, Achilleas Floudas1, Siobhan C. Wade1, Candice Low2, Douglas J. Veale2 and Ursula Fearon1, 1Molecular Rheumatology, School of Medicine, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland, 2Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland

    Background/Purpose: Tofacinitib (Pfizer) is an oral Janus kinase inhibitor, recently approved for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Although its mechanism…
  • Abstract Number: 1022 • 2018 ACR/ARHP Annual Meeting

    TNF-α Regulates Plasmacytoid Dendritic Cells By Suppressing IFN-α Production and Enhancing Th1 and Th17 Cell Differentiation

    Antonios Psarras1,2,3, Agne Antanaviciute4, Ian Carr4, Miriam Wittmann1,2, Paul Emery1,5, George C Tsokos6 and Edward M Vital1,2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, 4Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom, 5Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 6Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose: Human plasmacytoid dendritic cells (pDCs) play a vital role in modulating immune responses. pDCs can produce massive amounts of type I IFNs in response…
  • Abstract Number: 1023 • 2018 ACR/ARHP Annual Meeting

    Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis

    Isela Valera1 and Ram R. Singh2, 1Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, 2UCLA, Los Angeles, CA

    Background/Purpose: In bleomycin-induced model of systemic fibrosis and patients with systemic sclerosis, plasmacytoid DC (pDC) are unaffected or reduced systemically (spleen/peripheral blood) but they increase…
  • Abstract Number: 1111 • 2018 ACR/ARHP Annual Meeting

    CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis

    Clarissa Corinaldesi1, Yasser M El-Sherbiny2, Gemma Migneco3, Rebecca Ross1, Steve Holmes4, Clive McKimmie5 and Francesco Del Galdo1, 1Leeds Biomedical Research Centre and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, 3Institute of Cancer and Pathology, University of Leeds, Leeds, United Kingdom, 4Capella Biosciences, LTD, London, United Kingdom, 5Virus Host Interactions Team, Section of Infection and Immunity, University of Leeds, Leeds, United Kingdom

    Background/Purpose: Human plasmacytoid dendritic cells (pDCs) have been implicated in the pathogenesis of Systemic Sclerosis (SSc) through their ability to infiltrate the skin and secrete…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology